An observational study in IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome and Crohn Disease (CD), sponsored by American Laboratory Products Company. Completed at 1 site in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by American Laboratory Products Company · Observational
This study is evaluating the levels of calprotectin, a protein found in stool, in healthy adults. Calprotectin is a marker of inflammation in the intestines and can help doctors tell the difference between inflammatory bowel diseases (IBD), like Crohn's disease or ulcerative colitis, and non-inflammatory conditions like irritable bowel syndrome (IBS).
In this study, healthy volunteers aged 22 and older will collect a stool sample at home using a simple kit and mail it to the study site. The samples will be tested using a new laboratory method called the ALPCO Calprotectin CLIA assay. The goal is to confirm what level of calprotectin is considered "normal" in people without intestinal disease.
Participation involves just one stool sample, and there are no medical procedures. Volunteers will be compensated for their time. The study will help improve how doctors interpret calprotectin test results in clinical settings.
This study is designed to evaluate the expected (normal) values of calprotectin in the stool of healthy adults using the ALPCO Calprotectin CLIA assay, an investigational in vitro diagnostic test. Calprotectin is a protein released during intestinal inflammation and is commonly used as a non-invasive biomarker to assess gastrointestinal diseases. Elevated levels of fecal calprotectin can indicate active inflammation, particularly in patients with inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis. Conversely, low levels are typically associated with non-inflammatory conditions like irritable bowel syndrome (IBS).
The purpose of this study is to establish baseline (expected) calprotectin levels in individuals who do not have symptoms of IBD, IBS, or other chronic intestinal conditions. These expected values are essential to validate the performance of the ALPCO Calprotectin CLIA assay and to guide its use in differentiating inflammatory and non-inflammatory gastrointestinal conditions in clinical practice.
Approximately 120-150 healthy adult volunteers, aged 22 and older, will be enrolled at 1-2 U.S. clinical sites. Eligible participants will not have any history of chronic intestinal disorders, cancer, recent use of NSAIDs or GI medications, or active gastrointestinal symptoms. After providing informed consent, each participant will collect a stool sample at home using a provided sample collection kit. The sample will be returned to ALPCO by mail or delivery, where it will be analyzed in a laboratory using the study assay.
Stool samples will be processed, stored, and tested according to standardized procedures. The results of this study will be used to determine the reference cut-off value for a healthy population (currently hypothesized at 50 µg/g) and to support the performance claims of the ALPCO Calprotectin CLIA assay in future regulatory submissions.
Participants will be compensated for their participation. There is no direct medical benefit to participants, and the test results will not be shared with them. All samples and data will be handled confidentially, in accordance with Good Clinical Practice (GCP), U.S. FDA regulations, and HIPAA.
1,460 studies on the registry are indexed under Inflammatory Bowel Diseases; 438 are open to participants now.
This study's enrollment of 121 is below the median of 139 across 645 observational studies indexed under Inflammatory Bowel Diseases.
Browse Inflammatory Bowel Diseases studies →American Laboratory Products Company is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will enroll approximately 120 to 150 healthy adult volunteers, aged 22 years or older, from the general U.S. population. Participants must be asymptomatic with no history of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), gastrointestinal cancer, or other chronic intestinal conditions. Subjects must not be on immunosuppressive therapy, PPIs, H2 blockers, or regular NSAID use prior to sample collection. The goal is to represent a normal, healthy population to establish baseline calprotectin levels using the ALPCO Calprotectin CLIA assay.
No abdominal symptoms and no history of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), or other chronic intestinal disorders
May have undergone colonoscopy with negative findings within the past month or never undergone colonoscopy
Able and willing to provide a stool sample according to the collection protocol
Able to understand the study and sign the informed consent form (ICF)
Exclusion Criteria:
Known active intestinal cancer or history of intestinal cancer with abnormal clinical findings
Currently receiving chemotherapy or systemic immunosuppressive medications
Use of proton pump inhibitors (PPIs) or H2-receptor antagonists within the last 2 weeks
Use of NSAIDs (including aspirin) for 7 or more days in the past 2 weeks
Presence of gastrointestinal symptoms such as abdominal pain, diarrhea, altered appetite, weight loss, or anemia
Samples collected not following protocol requirements
Any other condition that, in the opinion of the investigator, may interfere with study participation or data validity
This group will include approximately 120 to 150 asymptomatic, healthy adults aged 22 years or older. Participants must have no history of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), gastrointestinal cancer, or chronic intestinal disorders. They must not be taking immunosuppressive therapy, proton pump inhibitors, H2 blockers, or NSAIDs as outlined in the exclusion criteria. Participants will collect a single stool sample at home using a provided kit and ship it to the sponsor site (ALPCO) for laboratory analysis. The stool samples will be tested using the ALPCO Calprotectin CLIA assay, a chemiluminescent immunoassay designed to measure fecal calprotectin levels. This group serves to establish reference (expected) calprotectin values in healthy individuals, which will support assay validation and performance claims.
Device: ALPCO Calprotectin CLIA
Measurement of calprotectin in feces
Establish the Expected Reference Range for Fecal Calprotectin in Healthy Adults
Determine the distribution and expected (normal) reference range of fecal calprotectin concentrations in healthy adults using the ALPCO Calprotectin CLIA assay. The outcome will confirm whether the predefined clinical cut-off value of \<50 µg/g accurately reflects a non-inflammatory baseline in an asymptomatic population.
Time frame: Within 2 months of sample collection
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
American Laboratory Products Company